WO1998057650A1

WO1998057650A1 - Antiathlete's foot composition

Info

Publication number: WO1998057650A1
Application number: PCT/JP1998/002586
Authority: WO
Inventors: Nobuaki Imai
Original assignee: Otsuka Pharmaceutical Co., Ltd.
Priority date: 1997-06-16
Filing date: 1998-06-12
Publication date: 1998-12-23
Also published as: AR016067A1; AU7674598A

Abstract

An antiathlete's foot composition characterized by comprising lactosucrose as the active ingredient. The composition is effective in the prevention and treatment of athlete's foot.

Description

Specification

Anti-athlete's foot composition

Technology minutes a

The present invention relates to an anti-athlete's foot composition.

Background g

It is known that skin diseases generally referred to as athlete's foot are mainly caused by fungi such as Trichophyton and filamentous fungi. Various treatments such as topical treatment, oral treatment, and physiotherapy have been developed and proposed, and various chemotherapeutic agents for such treatment have been researched and developed.However, this is still a breakthrough. There is no current situation.

Accordingly, an object of the present invention is to provide a new anti-athlete's foot drug, an anti-athlete's foot composition, a food form of an anti-athlete's foot food such as a drink, which is effective for the prevention and treatment of the above athlete's foot.

Another object of the present invention is to provide a method for preventing and treating the above athlete's foot.

The present inventor has conducted intensive studies for the above purpose, and as a result, has found a new fact that ingesting lactose sucrose gives a desired anti-athlete's foot effect. Here, the present invention has been completed.

¾ m © Display

According to the present invention, lactose cellulose (hereinafter referred to as "LS-" Is provided as an active ingredient.

The above composition preferably contains 0.5 to 70 g of L S in 100 g of the composition.

Further, according to the present invention, there is provided an anti-athlete's foot food for preventing and treating athlete's foot, which contains LS as an active ingredient.

The food is particularly preferably in the form of a beverage, the beverage comprising 100-70 g of LS 0.5-70 g and a buffer and having a pH of 4. It is preferably adjusted to 0 — 6.5.

Further according to the present invention there is provided the use of L S for the manufacture of an anti-athlete's foot composition.

In addition, according to the present invention, there is provided a method for preventing and treating athlete's foot that allows a human who is required to prevent or treat athlete's foot to receive an effective amount of LS.

Further, according to the present invention, there is provided a method for preventing and treating athlete's foot that allows a human who is required to prevent or treat athlete's foot to receive an effective amount of an anti-athlete's foot composition containing LS as an active ingredient.

It is essential that the anti-athlete's foot composition of the present invention contains LS as an active ingredient. The LS is a known substance represented by the following structural formula, and 0 — ^ — D—galactoviranoji No 1 (1 → 4) — 〇 1 1 D — Gnoreco Pirano Shinor 1 (1 — 2) — — D — This is displayed as Fractofuranoside.

Such LS is a known compound produced by various methods. The LS as the active ingredient of the present invention may be one obtained by any of the above methods (a reaction mixture and a purified product thereof). As the method, for example, as described in Japanese Patent Publication No. 57-18905, a reno-synthase derived from a genus of Aeronocta is used. A method of allowing a solution of sucrose and lactose to act, as described in JP-A-64-185090, a cell extract of a specific sporoboromyces genus Examples of the method include a method using a bacterium of the genus Oralella as described in JP-A-2-35095. ― The above S is 100 g in the anti-athlete's foot composition of the present invention,

It is preferable to contain about 0.5 to 70 g, preferably about 5 to 30 g.

The anti-athlete's foot composition of the present invention is prepared in a pharmaceutical form or a food form. The shape is not particularly limited as long as it can be taken or ingested, and may be, for example, a lump, a liquid, a syrup, a powder, or the like. For shaping into such a shape, a pharmaceutically acceptable carrier or an edible carrier such as a commonly used excipient or diluent can be used. In addition, the composition of the present invention in the above-mentioned various shapes may further contain various known additives such as a bulking agent, a sweetener, other saccharides, vitamins, flavors, coloring agents and the like. Can be done.

Specific forms of the composition of the present invention include, for example, liquid or powdered sweeteners, beverages such as soft drinks and milk drinks (drinking agents), breads, cooks, and the like. Examples include confectioneries such as candies, food forms such as health food forms, and pharmaceutical forms such as powders, powders, liquids, suspensions, tablets, and foaming agents.

The production of the composition of the present invention in the above-mentioned various forms is carried out by adding and mixing the above-mentioned various carriers. You can do it. ― For example, when the composition of the present invention is prepared in a food form, the amount of the active ingredient in the food form is appropriately determined based on the daily intake of the food described below. When formulated into a beverage form, the beverage generally contains about 0.5 to 70 g of LS as the active ingredient, preferably 100 ml, more preferably about 5 to 30 g X 1 It is prepared by dissolving in water or another dissolving agent or diluent so as to obtain a water content of 0 m 1. The beverage is preferably prepared by mixing an appropriate buffering agent to have a pH of about 4.0 to 6.5, preferably about 4.5 to 6.0. Good.

Here, as the buffer, typically, weak acids such as citric acid, tartaric acid, lactic acid, lingoic acid, and carbonic acid and salts thereof, for example, sodium citrate and sodium tartrate Examples thereof include sodium, sodium phosphate, sodium lactate, sodium lactate, sodium hydrogen phosphate, sodium carbonate, and sodium hydrogen carbonate. The mixing ratio of these components is appropriately determined from the range in which the obtained beverage maintains the above-mentioned appropriate pH range, and is usually up to 2% by weight, preferably about 0.05 to 0.3% by weight. obtain. This buffer helps stabilize L S in the resulting beverage.

Further, in the composition of the present invention in the form of a food such as the above-mentioned beverage, various sugars or sweeteners are added in the same manner as in a general beverage or the like. Can be added. Examples of the carbohydrate include monosaccharides such as glucose and fructoses, disaccharides such as manoleth and sucrose, dextrin and cyclodextrin. And sugar alcohols such as xylitol, erythritol and sorbitol. Examples of sweeteners include natural sweeteners (such as somatin, stevia extract, and glycerin), and synthetic sweeteners (such as saccharin and aspartame). You. The proportion of such sugars or sweeteners is usually up to 15% by weight, preferably up to about 13% by weight of the foodstuffs usually obtained.

Furthermore, in addition to the above-mentioned sugars or sweeteners, the composition of the present invention may contain various kinds of juices (concentrated juices) such as grapefruit, apple, orange, lemon, pineapple, banana, pear and the like. ); Vitamins (retinoyl palmitate, bisbenthiamin, riboflavin, pyridoxine hydrochloride, cyanokonokramin, sodium asconolevinate, nicotine) Water-soluble and fat-soluble vitamins, such as calcium acid amides, phenols, calcium phosphates, folic acid, piotin, coleciflucifer, oral bitumin, choline bitartrate, and tocopherol Flavoring agents; Coloring agents; Amino acids (sodium glutamate, glycine, alanine, sodium aspartate, etc.); Dietary fiber (polydextrin, black Chin, Kisanta Ngam Ara Biagamu, - Taste components (glutamic acid, inosinic acid, etc.); minerals and trace elements (sodium chloride, sodium acetate, magnesium sulfate, potassium chloride, chloride) Magnesium, magnesium carbonate, canolecidium chloride, dicalcium phosphate, sodium phosphate, calcium glycerate phosphate, ferrous sodium citrate , Manganese sulfate, copper sulfate, sodium iodide, potassium sonolevinate, zinc, manganese, copper, iodine, cobalt, etc.) _c inventive compositions that can have a this added blended if necessary with the Ru can and this be prepared by simply mixing the above components. The preparation method is not particularly limited, and all the necessary components may be mixed at the same time. In the case where both the oil component and the aqueous component are used, the oil component is previously added to an appropriate oil agent. And an aqueous solution of the water-soluble component can be emulsified using an emulsifier. The emulsification operation can be carried out according to a general method, for example, using a homomixer, a high-pressure homogenizer, or the like, according to a complete passage system or a circulation system. The above components are usually mixed or emulsified at room temperature, but a slight heating operation may be employed. The composition of the present invention thus prepared is filled into a suitable container, and then sterilized by heat sterilization, aseptic filtration or the like according to a conventional method to obtain a product. ― The composition of the present invention can also be prepared in the form of a suitable foam formulation that can be dissolved and dispersed in water, such as tablets, granules, powders, capsules, and the like. The foam formulation is prepared using sodium hydrogen carbonate and / or sodium carbonate as a foaming component and a neutralizing agent. Here, examples of the neutralizing agent include citric acid, tartaric acid, fumaric acid, asconolevic acid, lactic acid, and lingic acid. The mixing ratio of the foaming component and the neutralizing agent is preferably selected from the range of usually 8 to 60% by weight of the foaming component and 10 to 70% by weight of the neutralizing agent. Such effervescent preparations can be prepared according to the general method, for example direct powder compression or dry or wet granulation, using a further predetermined amount of calcium carbonate, if necessary. You.

The intake or dose of the composition of the present invention is appropriately determined depending on the purpose of use or the age, sex, weight, degree of disease, etc. of the person to whom the composition is to be applied, and is not particularly limited. _{(When the} composition of the present invention is a solid, generally, about 5 to 30 g of the preparation of the present invention is taken at a time, and more preferably, the solid is taken in 30 to 2 g of water. It is preferable to dissolve the drug in 100 ml and take it.When the present composition is in the form of a liquid such as a beverage, it is recommended to take about 30 to 200 ml per dose. The preferred daily intake or dose of the composition of the present invention is The amount is preferably such that about 2 to 50 g, preferably about 3 to 20 g of the active ingredient is ingested and taken in terms of the amount of the contained active ingredient.

Thus, the composition of the present invention can exert remarkable preventive and therapeutic effects against any of athlete's foot caused by various causative bacteria by taking or ingesting the composition.

BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, in order to explain the present invention in more detail, a preparation example of the composition of the present invention will be given as an example, and then a test for examining the anti-athlete's foot effect of the composition of the present invention will be described. Examples and clinical examples are given. In each example, parts and% are based on weight.

Examples 1 to 6

Each of the starting compounds was mixed and dissolved in water so as to have the composition shown in Table 1 below to prepare the composition of the present invention. In the formulation of each example, a fragrance and / or vitamins are appropriately blended. Each formulation was made up to 100 ml with water.

Example 7

Either mix the following components (additional amount of flavor, including coloring agent, total amount of 5 g) and prepare directly by tableting (powder), or weigh and mix each component and package (spray) , Or— Each component was weighed and mixed, granulated and dried, and then packaged (granules) to prepare respective preparations.

L S 5 5 P 3 4%

L — Asconolevinic acid 2 1%

L-tartaric acid 20%

sweetener

Bicarbonate sodium 2 1%

Sodium chloride

Lithium carbonate 0 5%

Total 100%

The above “LS55P” refers to a powder containing 55% of LS.

Examples 8 to 10

In the same manner as in Example 7, preparations of the present invention in the form of tablets, powders, and granules containing each component in a predetermined ratio and a small amount of cyanocobalamin, flavor and colorant were prepared. <Example 8 prescription>

L S 5 5 P 40%

L — Asconolevinic acid 10%

L _ tartaric acid 2 3%

Sweetener appropriate amount

22% sodium bicarbonate " Sodium citrate appropriate amount

Carbonate 0 · 4%

Total 100% (5 g total) <Example 9 prescription>

L S 5 5 P 40%

L — As conorelevic acid 1 1%

L-tartaric acid 2 3%

Sweetener appropriate amount

Bicarbonate sodium 2 2%

Ammonium citrate 0.8%

Trace amount of sodium citrate

0.4% of calcium carbonate

σ mouth I 100% (Total amount 4.6 g)

L S 5 5 P 40%

L-tartaric acid 2 9%

Sweetener j amount

Bicarbonate sodium 24%

Iron citrate ammonium 3.6%

Acid calcium 0.5%

OI 100% (4 g total) Examples 11 to 18

In the same manner as in Examples 7 to 10, foamed preparations having the compositions shown in Table 2 below were prepared.

Table 2

Examples 19 to 25

Each component (mg) shown in Table 3 below was mixed, and a chewable tablet was prepared by a direct compression method. Three

Example 2 6 3 4

The components shown in Table 4 below were mixed, and water was added to make the total amount 100 μm. Thus, the composition of the present invention in the form of a health drink was prepared. Four

Table 4 (continued)

Example 35 to 45

The components shown in Table 5 below were mixed, water was added to make the total amount 10 Oml, and the composition of the present invention in the form of a beverage was prepared. ₍ The gas volume value in the table is the same as that of the solution. Index indicating the amount of carbon dioxide contained calculated assuming that the volume of gaseous carbon dioxide dissolved is 1. Indicates that the amount of carbon oxide is large.

Five

Component No.Example No.

1 f ulflumuil Φ q

ϋ ϋ o D 0 ί 00 4 U q

Kn / /, Knϋ 丄 1 ώ 9 q 1 Q 0

0 Δ village * S ί σ Q 7 Q

0/7 0

0

¾ ¾ M ύ π i * ϊg (, g σ ^ no 1 丄 0 ϋ q 7

1 0 Furnace a 1

Tree, g σ 0

-fa ノ L Ό 丄

Funo, K Γ, No solution (V σ ^ 9 9 9

L L

Kuno Cho, Q Q

z ノ, τ 1η11 g rr ^ 0 0 L 0 Suitable C a ^ 適

i) Ngoic acid (ιησ ^ 4 o o

Lactic acid (mg ^ 8 2 20 sodium citrate (mg) 9 fl l 10 リ

洒 (P stone W ϋ t¾ '' n t Cm uig) fin 1 u Sodium phosphate (mg) 80 150 100 Calcium lactate (mg) 15 10 Sodium chloride Λ (mg) 4 1 1.5 Potassium chloride (mg) 3 2

Mac chloride, Nesium (mg) 2 1

Juice (%) 3 1 0.5 0 · 1 Flavor · Sweetener Appropriate amount Appropriate amount Appropriate amount Appropriate amount Appropriate amount Gas volume 3.0

PH 5.0 6.3 5.8 4.9 5.8 5.3 5 (continued)

Constituents Example No.

(In 100 ml) 41 42 43 44 45 Ratatosucrose <: g) 4 10 15 7 13 Isomerized sugar (g) 5--9-Purified sucrose (g) 3----Fructose (g) 3- --60 Bud sugar (g) 3--24 Citric acid (mg)-25--Tartaric acid (mg)---10-Linguic acid (mg) 4.5 Mono--Lactic acid (Rag)--10 Sodium monocitrate (mg)-100 55 70-Sodium tartrate (mg)-30 20 Linko, sodium acid (mg) 45-10-50 Lactic acid or calcium (rag)---5 Sodium chloride (mg) 2

Potassium chloride (mg) 5 1 1 Mac chloride, Nesium (mg) 1

Fruit juice (%) 2 0.3 Flavors / sweeteners Appropriate amount Appropriate amount Appropriate amount Appropriate amount Gas volume 2.0 2.5 2.3 3.3 1.5

PH 5.5 5.6 6.4 5.6 5.9 Test example 1

From June to August 1997, a solution of 5 g of lactose in 50 ml of water (10 men) with athlete's foot 1) was taken on a daily basis and its effect on athlete's foot was examined. However, each patient was not allowed to use any other drug for athlete's foot. O

Table 6 and Table 7 below summarize the patient's age, number of days of solution consumption, drinking status, pre-drinking symptoms and onset time, and the degree of improvement of athlete's foot symptoms (symptom improvement evaluation, remarks and comprehensive evaluation) by this test in Tables 6 and 7 below. .

In addition, the above-mentioned comprehensive evaluation is indicated by symbols according to the following five-level evaluation.

+ + +; The symptoms of athlete's foot disappeared.

+ +; Significant improvement in the symptoms of athlete's foot was observed.

+; Improvement of subjective symptoms such as pruritus was confirmed.

Soil: No effect on athlete's foot could be confirmed.

1; Athlete's foot symptoms worsened rather. 6

Subject Age Drinking days Drinking conditions Pre-drinking symptoms Onset

YT 46 70 1 per day Fingers on both feet, soles,

I S 43 45 1 day 1 right toe, sole, all seasons, erosion, dwarf

HK 46 13 1 day 1 part of left ring finger and little finger M part,

So feeling,

NT 46 40 1 day 1 fingertip of right ring finger and little finger, itching,

UK 47 40 6 per week Right foot finger and little finger HU All season

TT 44 70 1 per day 中 Middle finger, finger H, finger section, all season pruritus, erosion,

KO 53 60 week 6 left middle finger, water range IS rain

YT 41 40 5 / week Both soles, left thumb, dwarf rainy season, summer

SK 59 42 5 per week 两 Toe H,, all seasons

ST 46 40 5 weekly rainy season, summer

Table Ί

From the above results, it is clear that the use of the anti-athlete's foot composition of the present invention can improve the symptoms of athlete's foot and suppress the deterioration of the symptoms of athlete's foot.

Test example 2

(1) Test method

Raktoshook in patients with athlete's foot (23 patients with superficial dermatomycosis (vesicle-type, interdigital toe foot tinea)) A single solution of 5 g of loin dissolved in 50 ml of water was ingested once a day for 8 weeks, and after 2, 4, 6, and 8 weeks, subjective symptoms were observed. It was examined whether there was improvement in pruritus and skin findings (redness, papules, blisters / pustules, maceration, sores and dust). At the same time, a mycological examination was performed. However, during the study period, each patient should not use any other drugs that may affect athlete's foot treatment (antibiotics, antibacterials, antifungals, steroids, antiallergics, etc.) I didn't do it.

(2) Improvement of subjective symptoms

Subjective symptoms were evaluated by questionnaire survey of each patient, and evaluated on a 5-point scale according to the following criteria.

Subjective symptom criteria:

4: Strong itching (going unconsciously) 3: Always worried (Itching all day)

2: Sometimes worrisome (it becomes itchy several times a day)

1: Not much disturbed (it becomes itchy once a day)

0: Don't mind (no itching)

Using the evaluation score at the start of the test as a reference value, calculate the difference between this score and each evaluation score after 2, 4, 6, and 8 weeks, and divide the difference by the reference value to obtain the percentage of the value that improves subjective symptoms Ο calculated as a rate Based on the subjective symptom improvement rate obtained above, the subjective symptom improvement effect was determined according to the following criteria.

Significant improvement: improvement rate of 67 to 100%

Improvement: Improvement rate 34 to 67%

Slight improvement: improvement rate 1-33%

No change: 0% improvement rate

Deterioration: Improvement rate less than 0%

(3) Examination of improvement effect on skin findings

For skin findings, each of the above symptoms (redness, papules, blisters, pustules, maceration, erosions, and scales) were evaluated on a 5-point scale according to the following criteria, and the severity was determined by the total score. In addition, the skin finding improvement rate was determined as follows, and the improvement effect was determined from the improvement rate in the same manner as described above.

Skin finding criteria:

4: Symptoms are strong

3: Moderate symptoms

2: Symptoms are mild

1: Symptoms are minor

0: No symptoms are observed

Severity rating:

Severe: Total score of 12 or more

Moderate: A total score of 8 to 11 ― Mild: those with a total score of 4 to 7

Minor: Items with a total score of 1 to 3

Healing: those with a total evaluation score of 0

Using the total score at the start of the test as a reference value, find the difference between this and the total score at 2, 4, 6, and 8 weeks later, and divide this difference by the reference value. The percentage was calculated as the skin finding improvement rate.

(4) Overall evaluation

The above evaluation score of subjective symptoms and the total evaluation score of skin findings are added to obtain a difference between the sum and the sum at the start of the test (reference value). The percentage was calculated as the overall improvement rate.

From the thus obtained overall improvement rate, the anti-athlete's foot composition of the present invention was evaluated according to the following criteria.

Evaluation ：

Significant effect: Overall improvement rate 67 to 100%

Effective: Overall improvement rate 3 4 to 6 7%

Somewhat effective: overall improvement rate 1 to 33%

Invalid: Overall improvement rate 0%

Deterioration: Overall improvement rate less than 0%

(5) Result

The results obtained are shown below. ― At 6 and 8 weeks after the start of the study, there was a statistically significant difference between the subjective symptom evaluation points and the study start.

At 8 weeks after the start of the study, the subjective symptom improvement rate was judged to be marked improvement in 8 cases (35%) and improvement in 2 cases (9%), and all the cases remained unchanged.

Regarding the skin findings, the scale was evaluated at the scale at 2, 4, 6, and 8 weeks after the start of the test, and the maceration was evaluated at 2, 4, and 8 weeks after the start of the test, respectively. Compared with, it was recognized that there was a statistically significant difference.

There was no statistically significant difference in redness and rash even after 8 weeks.

At 8 weeks after the start of the test, the rate of improvement in skin findings was marked in 5 cases (22%), improved in 6 cases (26%), slightly improved in 3 cases (13%), and remained unchanged. Eight cases (35%) and one case (4%) worsened.

In the evaluation of the anti-athlete's foot composition according to the present invention, which was determined from the overall improvement rate, 6 cases (26%), 5 cases (22%), 5 cases (22%) Seven cases (30%) were invalid.

In general, the effectiveness of a drug is determined by the above-mentioned total number of excellent and effective cases, and the composition of the present invention has a total of 11 cases. (48%), which is considered valid.

(6) Mycological test results

In addition, according to the mycological examination performed at the same time, that is, the results of direct microscopic observation of the presence or absence of bacteria in the affected tissue piece, the presence of bacteria was observed in all cases at the start of the test. Two weeks after the start of the test, the presence of bacteria was not observed (negative) in 2 out of 23 cases (9%). The number of patients who became negative gradually increased thereafter, to 3 cases (13%) 4 weeks after the study started, to 6 cases 6 weeks after the study started, and to 8 weeks after the study started. Became eight cases.

From this, it can be seen that according to the continuous ingestion of the anti-athlete's foot composition of the present invention, the bacterial negative rate increases in proportion to the number of days of ingestion, and the therapeutic effect on athlete's foot becomes remarkable.

Clinical case 1

For a male patient (30 years old) who has been affected by athlete's foot for about 3 years, 50 ml of the composition of the present invention containing 5 g of LS is administered at a rate of 50 ml per week for 3 months at a rate of 15 months. Ingested.

As a result, about one year after the start of ingestion, remarkable alleviation of athlete's foot symptoms was observed, and there was no athlete's foot symptom thereafter.

Clinical case 2

For a female patient (49 years old) who has been affected by athlete's foot for about 2 years, 50 m 1 of the present composition in the form of an aqueous solution containing 5 g of LS is administered They were ingested at a rate of 4 per week for 5 months.

As a result, marked relief of athlete's foot symptoms was observed about 2 months after the start of ingestion. Since then, there have been no athlete's foot symptoms. Clinical case 3

As a result of ingesting 50 ml of the present composition in the form of an aqueous solution containing 5 g of LS at a rate of 1 bottle per day to a female patient (60 years old) having a period of athlete's foot of about 3 years, 1 0 days later, the itch disappeared, and there has been no athlete's foot symptoms for about one year up to the present.

Clinical case 4

To a male patient (38 years old) who has a period of athlete's foot for about 5 years, 50 ml of the present composition in the form of an aqueous solution containing 5 g of LS is administered daily at an average rate of 0.5 per day to 2 patients. Ingested for months. As a result, a marked improvement in athlete's foot symptoms was observed about one month after the start of ingestion, and there were no athlete's foot symptoms thereafter.

Clinical case 5

For a female patient (29 years old) who has been affected by athlete's foot for about 4 years, one 50 ml of the present composition in the form of an aqueous solution containing 5 g of LS is taken at an average of 1 bottle per day for 16 months. Ingested.

As a result, about 4 months after the start of ingestion, the athlete's foot symptoms were alleviated, and subsequently, the athlete's foot symptoms did not appear.

Clinical Case 6 ― A male patient (41 years old), who has been affected by athlete's foot for about 25 years, receives 50 ml of the composition of the present invention in the form of an aqueous solution containing 5 g of LS at a rate of 5 bottles per week for 2 years. I let it.

As a result, about one year after the start of ingestion, marked relief of athlete's foot symptoms was observed, and thereafter, athlete's foot symptoms did not occur.

Clinical case 7

A 50-year-old male patient (59-year-old, using a commercially available anti-athlete's foot drug) of about 40 years with 50 ml of an aqueous composition containing 5 g of LS was administered at a rate of 50 ml per day. For 2 years.

As a result, marked relief of athlete's foot symptoms was observed about 3 months after the start of ingestion, and there were no athlete's foot symptoms thereafter.

Industrial applicability

The composition of the present invention, when taken or ingested, can exert an excellent preventive and therapeutic effect against athlete's foot due to various causative bacteria, and is useful as an anti-athlete's foot drug.

Claims

The scope of the claims

An anti-athlete's foot drug consisting of lactose.

An anti-athlete's foot composition containing lactosucrose as an active ingredient.

In 100 g of the composition, lactose closet is added.

3. The anti-athlete's foot composition according to claim 2, comprising 0.5 to 70 g.

The anti-athlete's foot composition according to claim 2, which is in a beverage form.

100 g of the composition contains 0.5 to 170 g of lactose cellulose and a buffer, and the pH is adjusted to 4.0 to 6.5. Item 6. The anti-athlete's foot composition according to Item 4.

6 Anti-athlete's foot diet for preventing or treating athlete's foot containing lactose cellulose as an active ingredient απο

7 0.5 kg of lactose in 100 g of food

7. The anti-athlete's foot food according to claim 6, comprising 70 g.

8. The anti-athlete's foot food according to claim 6, which is in the form of a beverage.

9 100 g of beverage contains 0.5 to 70 g of lactose cellulose and a buffer, and the pH is 4.0 —

The anti-athlete's foot diet according to claim 8, which is adjusted to 6.5.

0 Use of lactose for the production of anti-athlete's foot drugs. one 1 Use of lactose cellulose for the manufacture of an anti-athlete's foot composition.

2 The use according to claim 11, wherein the anti-athlete's foot composition contains 0.5 to 70 g of lactose in 100 g of the composition.

3. The use according to claim 11, wherein the anti-athlete's foot composition is in the form of a beverage.

(4) The anti-athlete's foot composition contains 0.5 to 70 g of lactose cellulose and 100 g of buffer in 100 g of the composition, and has a pH of 4.0 — 14. Use according to claim 13 adjusted to 6.5.

5 A method for preventing and treating athlete's foot that causes a human who is required to prevent or treat athlete's foot to receive an effective amount of lactose.

6 A method for preventing and treating athlete's foot, in which a human who is required to prevent or treat athlete's foot is ingested with an effective amount of an anti-athlete's foot composition containing lactose as an active ingredient.

7. The prevention or treatment of athlete's foot according to claim 16, wherein the anti-athlete's foot composition contains 0.5 to 70 g of lactose in 100 g of the composition. Method.

8. The method for preventing or treating athlete's foot according to claim 16, wherein the anti-athlete's foot composition is in the form of a beverage. ― 9 The anti-athlete's foot composition comprises 0.5 to 70 g of lactose cellulose in 100 g of the composition and a buffer, and has a pH of 4.0 to 4.0. The method for preventing and treating athlete's foot according to claim 16, which is adjusted to 6.5.